This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prognosis/ Outcomes  • Venous Thromboembolism  • Alert me on articles by topic

Linda S. Elting, DrPH; Carmelita P. Escalante, MD; Catherine Cooksley, DrPH; Elenir B. C. Avritscher, MD, MBA; Danna Kurtin, PhD; Lois Hamblin, BA; Shikha Gupta Khosla, MD; Edgardo Rivera, MD

Arch Intern Med. 2004;164:1653-1661.

Background  Although deep venous thrombosis (DVT) often complicates the clinical course in patients with cancer, few studies of the outcomes of DVT in this population have been published. Furthermore, the cost of DVT is largely undescribed. We herein report the largest study of DVT in this population to date.

Methods  We reviewed the medical records of 529 consecutive cancer patients in whom DVT developed from January 1, 1994, through December 31, 1997, and followed up these patients through December 31, 2000, for outcomes. The cost of hospitalization was obtained from our hospital's cost-accounting system and inflated to 2002 US dollars using the Consumer Price Index for Medical Care. Logistic regression was used to identify factors that were associated with a high risk of poor outcomes.

Results  The most common complication of DVT was bleeding, which occurred in 13% of patients. Pulmonary embolus occurred in 4%. Five patients (1%) died of complications of DVT and 5 (1%) of complications of anticoagulation. Recurrence of DVT was common (17% overall), particularly among those who had inferior vena cava filters (32%; P<.001) or a previous episode of DVT (P = .03). All but 4 patients were hospitalized for initial anticoagulation therapy, for a mean of 11 days. The mean cost of hospitalization was 2002 US $20 065.

Conclusions  Among patients with cancer, DVT frequently is associated with serious clinical outcomes. Its treatment is resource intensive and costly. More effective agents and less costly management strategies could have a significant impact on the outcomes and cost of DVT in this population.

From the Section of Health Services Research, Department of Biostatistics (Drs Elting, Cooksley, Avritscher, and Khosla), and the Departments of General Internal Medicine (Dr Escalante), Faculty Academic Affairs (Dr Kurtin), Radiation Oncology (Ms Hamblin), and Breast Medical Oncology (Dr Rivera), The University of Texas M. D. Anderson Cancer Center, Houston. The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Geerts et al.
Chest 2008;133:381S-453S.
ABSTRACT | FULL TEXT  

Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana et al.
Blood 2008;111:4902-4907.
ABSTRACT | FULL TEXT  

Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer
Falanga et al.
Am Soc Clin Oncol Ed Book 2008;2008:258-268.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman et al.
JCO 2007;25:5490-5505.
ABSTRACT | FULL TEXT  

Thromboembolism in Hospitalized Neutropenic Cancer Patients
Khorana et al.
JCO 2006;24:484-490.
ABSTRACT | FULL TEXT  

How I treat venous thromboembolism in patients with cancer
Prandoni
Blood 2005;106:4027-4033.
ABSTRACT | FULL TEXT